1Lear SA, Humphries KH, Kohli S, et al. Visceral adipose tissue accumulation differs according to ethnic background: results of the Muiticultural Community Health Assessment Trial(M-CHAT)[J]. Am J Clin Nutr, 2007, 86(2): 353-359.
2Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2012, 8(12): 728-742.
3Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of<7% without weight gain or bypoglycaemia in type 2 diabetes: a recta-analysis of the liraglutide clinical trial Drogramme[Jl. Diabetes Obes Metab. 2012. 14(1): 77-82.
4Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[J]. Curr Med Res Opin, 2008, 24(1): 275-286.
5Kaur P, Mishra SK, Mithal A, et al. Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India[J]. Indian J Endocrinol Metab, 2014, 18(1): 77-82.
6Li C J, Li J, Zhang QM, et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity[J]. Cardiovasc Diabetol, 2012, 11: 142.
8Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta- analyses ofrandomised controlled trials[J]. Bri Med J, 2012, 344: d7771.
9Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes(LEAD-1 SU)[J]. Diabet Med, 2009, 26(3): 268-278.
10Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD(liraglutide effect and action in diabetes)-2 study[J]. Diabetes Care, 2009, 32(1): 84-90.
